Gilead and Galapagos NV’s Filgotinib (JAK1i) Achieves Primary Endpoints for P-II TORTUGA study in AS patients

Gilead and Galapagos NV’s Filgotinib (JAK1i) Achieves Primary Endpoints for P-II TORTUGA study in AS patients

Shots:

  • The P-II TORTUGA study is assessing safety and efficacy in moderate to severe ankylosing spondylitis (AS) adults in ratio of 1:1 administering filgotinib 200 mg or PBO qw for 12 wks.
  • TORTUGA results (N=116): improvement in AS disease, ASAS20 response (76% vs 40%), ASDAS (-1.5 vs -0.6) with no new safety signals and deaths observed in study
  • TORTUGA study was conducted in Belgium, Bulgaria, Czech Republic, Estonia, Poland, Spain and Ukraine. Additionally, Filgotinib is being assessed in RA (FINCH P-III), CD (SELECTION P-III) UC

Click here to read full press release/ article | Ref: Gilead | Image: Wall Street